Rationally designed synthetic inhibitors of retroviral proteases inhibit the processing of viral polyproteins in cultures of human immunodeficiency virus type 1 (HIV-1)-infected T lymphocytes and, as a result, inhibit the infectivity of HIV-1 for such cultures. The ability of HIV-1 protease inhibitors to suppress replication of the C-type retrovirus Rauscher murine leukemia virus (R-MuLV) and the HWV-related lentivirus simian immunodeficiency virus (SIV) was examined in plaque reduction assays and syncytium reduction assays, respectively. Three of seven compounds examined blocked production of infectious R-MuLV, with 50% inhibitory concentrations of c 1,M. Little or no cellular cytotoxicity was detectable at concentrations up to 100 ,uM. The same compounds which inhibited the infectivity of HWV-i also produced activity against SWV and R-MuLV. Electron microscopic examination revealed the presence of many virions with atypical morphologies in cultures treated with the active compounds. Morphometric analysis demonstrated that the active compounds reduced the number of membrane-associated virus particles. These results demonstrate that synthetic peptide analog inhibitors of retroviral proteases significantly inhibit proteolytic processing of the gag polyproteins of R-MuLV and SIV and inhibit the replication of these retroviruses. These results are similar to those for inhibition of HIV-1 infectivity by these compounds, and thus, R-MuLV and SIV might be suitable models for the in vivo evaluation of the antiretroviral activities of these protease inhibitors.
Maturation of C-type retroviruses as well as the lentivirus human immunodeficiency virus type 1 (HIV-1) requires the action of a virally encoded protease (4, 9, 13, 14, 28, 32) . Retroviral mRNA is translated into polyproteins which are modified posttranslationally before assembly into immature virions and subsequent release from the infected cell (16, 29) . Immature particles are not infectious, have undetectable or low levels of reverse transcriptase (RT) activity, and characteristically appear spherical with annular cores in electron micrographs of sectioned material (8, 18) . Activation of the nascent viral protease within the immature virus particle apparently occurs after detachment of immature virions from the cell membrane (16, 22) . The activated protease cleaves the retroviral polyproteins at specific sites to produce the functional structural proteins and enzymes of the virus. The acquisition of infectivity is also accompanied by a characteristic change in morphology, from an annular to a dense core (8, 36) . Inhibition of the function of retroviral proteases by mutation (9, 13-15, 24, 28, 32) or use of specific inhibitors (18, 19, 21, 30) results in the formation of immature, noninfectious particles, and such studies have established the central roles of these viral enzymes in the process of virus maturation.
Retroviral proteases, which form homodimers in the ac-tive state (20, 23, 25, 26, 35) , belong to the class of aspartic proteases, all of which contain a pair of highly conserved regions composed of two hydrophobic amino acids followed by the characteristic sequence Asp-Thr/Ser-Gly (12, 16, 20) .
The overall conservation in tertiary and quaternary structures, especially in the region of the active site of retroviral proteases, leads to similarities in the cleavage site sequences which they recognize (16, 27) . These similarities led us to examine the possibility that the infectivities of animal retroviruses might be inhibited by synthetic protease inhibitors which have previously demonstrated activity against HIV-1 (18, 21) . If protease inhibitors had similar effects on animal retroviruses, animal retrovirus models could serve as experimental systems for investigating the consequences of viral protease inhibition in vivo and, thus, as a guide for the preclinical development of protease inhibitors for AIDS therapy. Elucidation of the structure, mechanism of action, and substrate specificity of HIV-1 protease has led to the design of peptide substrate analogs in which the scissile dipeptide linkage is replaced with a nonscissile hydroxyethylene isostere analog (5, 6) . Such synthetic peptide analogs inhibit the processing of viral polyproteins in T lymphocytes infected with HIV-1 and reduce viral infectivity (5, 21) . In (5, 6) . Inhibitors were characterized by high-pressure liquid chromatography, proton nuclear magnetic resonance, and fast-atom bombardment mass spectrometry. Inhibition constants for compounds 1 to 7 against HIV-1 protease were determined as described previously (5, 6) . Peptide analog inhibitors were dissolved in dimethyl sulfoxide at a concentration of 10 mM, diluted in complete tissue culture medium, and tested at a maximum concentration of 20 ,uM. Protease inhibitors were coded before testing so that evaluations of antiviral activity against R-MuLV and SIV were done in a blinded fashion. 3'-Azido-2',3'-dideoxythymidine (AZT; generously provided by Burroughs-Wellcome, Research Triangle Park, N.C.) was used as the positive control for the antiviral assays, and it was dissolved directly in tissue culture medium.
UV-XC assay. The UV-XC assay involves a two-stage culture procedure that is used to enumerate the number of PFU (31) as described previously (3) . Briefly, subconfluent monolayers of SC-1 cells were infected with appropriate dilutions of virus samples (50 to 100 PFU per well). After 3 days, the cultures were irradiated with a short-wave (254 nm) UV lamp at a total dose of 1,200 ergs/mm2, and XC cells were added. After 3 more days, the cultures were fixed and stained. Plaques in the cell monolayer were counted with the aid of a dissecting microscope.
Plaque reduction assay for R-MuLV. A modification of the UV-XC assay was used to determine the antiviral activities of the compounds for R-MuLV. Antiviral compounds were added to the culture medium after adsorption of the virus and remained in the culture medium for 3 days. Toxicity was then measured by reduction in uptake of the tetrazolium dye 3-(4,5 -dimethylthiazol -2 -yl) -2,5 -diphenyltetrazolium bromide. In replicate plates, cells were then irradiated, and XC cells were added as described above. The concentrations for 50% and 90% inhibition of plaque production and 20% cellular cytotoxicity were estimated with the Dose Effect Analysis program of Chou and Chou (Biosoft).
SIVsmlpbj infectivity assay. Virus dilutions were added in duplicate to AA2 cells (10,000 cells per well) in 96-well plates in RPMI 1640 medium supplemented with 10% fetal bovine serum-5% glutamine-0.5% gentamicin-2 p.g of polybrene per ml. The compounds and virus were added to the cells to give a total volume of 200 ,ul. The cultures were held for 10 days, with feeding (100 ,ul) on day 3 and replacement of 100 ,ul on day 7. Cultures were observed for syncytium production at days 7 and 10. Wells were scored as positive if any syncytia were observed. Culture supernatants were collected on day 10 for SIV p27 quantitation by using a SIV p27 enzyme-linked immunosorbent assay (Coulter).
RT assay for R-MuLV. The procedure for measuring RT activity has been described previously (3) c Inhibition of recombinant HIV-1 protease in a cell-free system, measured as previously described (5, 6, 21 
RESULTS
Effect of protease inhibitors on R-MuLV. The activities of the protease inhibitors against HIV-1 protease in cell-free systems, as well as their abilities to inhibit HIV-1 and R-MuLV infectivities in cell culture, are given in Table 1 . Compounds 3, 5, and 7 inhibited production of infectious R-MuLV, with 50% inhibitory concentrations of 0.82 ,uM for compound 3, 0.67 ,uM for compound 5, and 1.0 ,uM for compound 7. Compound 2 also displayed dose-dependent antiviral activity at greater than 10-fold higher concentrations. In contrast, compounds 1, 4, and 6 did not reduce the number of PFU. No cellular cytotoxicity was detectable at concentrations up to 100 puM with any of the seven compounds.
Inhibition of R-MuLV protease. Cell extracts of inhibitortreated cells acutely infected with R-MuLV were examined by Western blotting to determine whether these HIV-1 protease inhibitors can also inhibit the processing of R-MuLV gag polyproteins. R-MuLV-infected SC-1 cells treated with two of the HIV-1 protease inhibitors, compounds 3 and 5 at 20 or 10 ,uM, contained greatly reduced amounts of the p30 gag protein, indicating that these compounds inhibit gag processing or replication of R-MuLV (Fig. 2) . Untreated R-MuLV controls contained p30, and uninfected untreated controls contained no p30 band. The protein bands detected in the 50-to 80-kDa range represent host proteins that were reactive with the antibody that we used, since these were detected in uninfected cells extracts. It seems likely that, because of the inhibition of spread of virus to susceptible cells, insufficient levels of viral core proteins were made in the treated cells to detect PrO5gag or its processing intermediates.
Effects of protease inhibitors on SIVsm/pbj. The synthetic protease inhibitors inhibited replication of SIV in assays of syncytium reduction and SIV p27 production at similar concentrations ( Table 1 ). All of the compounds except compounds 4 and 6 were able to block SIV p27 production by 100 tissue culture infective doses. Compounds 3, 5, and 7 were the most potent and completely inhibited syncytium production by SIV at concentrations <1.3 ,uM ( (Fig. 4) . The majority of virions produced by all cultures, except those treated with compound 3, were normal in both size and structure, but abnormal extracellular particles in addition to normal virions were observed in some cultures (Fig. 4) . Cultures treated with compound 3 in particular produced extracellular particles with the annular cores characteristic of immature virions, in addition to some other particles with abnormal morphologies. Increased numbers of immature virions with annular cores, similar in appearance to immature HIV-1 particles (8) , were observed in cultures treated with AZT and compounds 2, 3, 5, 6, and 7. Additionally, we noted particles lacking a condensed core and particles containing multiple cores. Cultures treated with AZT and compounds 3, 5, and 7 showed a reduction in the production of mature (infectious) particles (Fig. 4) . DISCUSSION The studies described here revealed striking similarities in the in vitro antiviral activities of rationally designed synthetic protease inhibitors against two different animal retroviruses: SIV, a simian lentivirus, and R-MuLV, a murine C-type virus. The same compounds, namely, compounds 3, 5, and 7, were highly active against both viruses in a number of different assay systems. Compound 2 had much less activity against both viruses, and compounds 1, 4, and 6 had little or no activity. Even more striking was their similar activities against HIV-1. As reported previously (5, 18, 21, 22), these same protease inhibitors inhibit the processing of viral polyproteins in cultures of human T lymphocytes chronically infected with HIV-1 and, consequently, the production of infectious virus particles. As shown in Table 1 , compounds 3, 5, and 7 had the greatest activities against HIV-1. Thus, the same three protease inhibitors inhibited the infectivities of R-MuLV, SIV, and HIV-1.
It is not surprising that the same compounds were active against both HIV-1 and SIV because they are related lentiviruses which share similar genetic organizations and morphologies. Indeed, several inhibitors related to the compounds listed in Table 1 , including compound 4, exhibit similar inhibition constants with the recombinant proteases of HIV-1 and SIVmac (10) . Furthermore, the antiviral activities of HIV-1 protease inhibitors in cell culture experiments with SIVmGC have also been reported (1). However, the striking similarities in the biological effects of this group of compounds against lentiviruses and murine C-type retroviruses may not have been so predictable. Overall, HIV and the MuLVs display limited sequence homology except for two highly conserved domains, one of which encompasses the protease enzyme's active site (12, 16, 20) . In the proteases of these viruses, as in all known retroviral proteases, the active site includes the prototypic Asp-Thr-Gly sequence, from which the aspartic proteases derive their name (12, 16, 20) . In all aspartic proteases, this sequence is preceded by two hydrophobic residues, Leu-Leu for HIV and Leu-Val for MuLV (12, 16, 20) . As a result of these and other structural similarities, the proteases of HIV and MuLV share similar substrate cleavage sequence specificities (16, 27) . A typical cleavage site sequence in the polyprotein precursors of these retroviruses has the sequence Ser (or Thr)-X-Y-Phe (or Tyr)*Pro-Z, in which the Phe-Pro bond is scissile and amino acids X, Y, and Z are commonly hydrophobic residues (16, 27 Electron microscopic examination of infected, treated cultures was consistent with this explanation in that few, if any, membrane-associated virus particles were detected in cultures treated with compounds 3, 5, or 7. Moreover, many virions in these cultures had altered morphologies as determined by electron microscopy. At the plasma membrane of infected cells, newly synthesized retroviral polyproteins are assembled into immature, noninfectious virions which are then released from the cell surface (4, 8, 13, 14, 28) . Such immature particles have a characteristic spherical appearance with annular cores. Maturation of the virions, which makes them infectious, requires proteolytic processing by the retroviral protease, which specifically cleaves the viral polyproteins. The collapse of the annular core during maturation causes the core to change to the dense appearance characteristic of infectious particles (8, 36) . The presence of immature particles in cultures treated with a protease inhibitor indicates that interruption of polyprotein processing by protease inhibitors leads to a block in virus maturation. This observation is consistent with the interpretation that, at the least, protease inhibitors interfere with viral infectivity by preventing processing of retroviral polyproteins.
In summary, the results presented here, combined with the results of previous studies (5, 18, 21, 22) of the activities of these compounds against HIV-1, demonstrate that the selected viral protease inhibitors have broad spectra of activity. The results of the present study indicate that murine and simian retrovirus models may be suitable systems for the preclinical development of some protease inhibitors. Convenient, reliable, and meaningful animal models should prove to be of great value in optimizing conditions for administration of these agents. Even though R-MuLV does not represent a model for HIV pathogenesis, issues affecting agent selection, such as route of delivery, formulation, pharmacokinetics, and bioavailability, can readily be addressed in such systems. 
